RoundTable Healthcare Partners Acquires Colorescience, Bolstering Portfolio with Fast-Growing Skincare Brand

In a strategic move within the competitive prestige skincare sector, private equity firm RoundTable Healthcare Partners announced Monday its acquisition of Colorescience, a clinically-backed brand specializing in sun protection and treatment-infused cosmetics. Financial terms of the deal were not disclosed, but industry analysts note the brand's revenue is nearing $100 million.

The acquisition sees Colorescience transition from ownership under 1315 Capital and a group of shareholders to RoundTable's growing portfolio of healthcare and wellness investments. The brand, which debuted over 25 years ago and was once part of SkinMedica, has carved a significant niche by bridging medical-grade efficacy with consumer accessibility.

"Our journey since 2013 has been about building more than a brand—it's been about building trust and delivering tangible results for our customers," said Mary Fisher, CEO of Colorescience. "We are energized to partner with RoundTable, whose operational philosophy and deep industry expertise resonate with our core mission as we accelerate our next growth chapter."

Tim Connors, Managing Partner at RoundTable and newly appointed Chairman of Colorescience's board, highlighted the brand's unique market position. "Colorescience has cultivated a powerful, advocacy-driven community through a science-first product portfolio. We see substantial potential to scale its impact and reach," Connors stated.

Adele Oliva, Founding Partner of 1315 Capital, reflected on the transition: "Supporting Colorescience's life-protecting mission has been a privilege. We have great confidence in RoundTable's ability to steward the brand's impressive trajectory, based on our positive history of collaboration."

Market Impact & Analysis: This transaction underscores private equity's sustained appetite for dermatology-focused beauty brands with proven clinical credentials. In an era where consumers increasingly seek products with medical endorsements, Colorescience's hybrid offering of sunscreen and treatment cosmetics presents a scalable model for growth in both professional and direct-to-consumer channels.

Reader Reactions:

Dr. Anya Sharma, Dermatologist, New York: "As a practitioner, I've recommended Colorescience for years. This acquisition could mean greater investment in R&D and education, which is a win for patient care, provided the clinical integrity remains paramount."

Marcus Lee, Beauty Industry Analyst: "This is a logical consolidation. RoundTable has a strong track record in healthcare. Their resources can optimize Colorescience's supply chain and professional distribution, potentially challenging larger players in the medical aesthetics space."

Elena Rodriguez, Consumer Advocate & Blogger: "Here we go again. Another independent-feeling brand gets swallowed by private equity. I'm deeply skeptical. Will quality and innovation take a backseat to profit margins and cost-cutting? History isn't reassuring."

Robert Chen, Portfolio Manager: "The ~$100M sales figure signals a mature, cash-flow-positive asset. For RoundTable, this isn't a turnaround play but an acceleration bet on a brand already in growth mode—a typically lower-risk strategy in today's market."